Privia Health Group, Inc. (NASDAQ:PRVA) EVP Thomas Bartrum Sells 1,506 Shares

Privia Health Group, Inc. (NASDAQ:PRVAGet Free Report) EVP Thomas Bartrum sold 1,506 shares of Privia Health Group stock in a transaction on Friday, May 10th. The stock was sold at an average price of $17.88, for a total value of $26,927.28. Following the transaction, the executive vice president now directly owns 102,356 shares of the company’s stock, valued at approximately $1,830,125.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Thomas Bartrum also recently made the following trade(s):

  • On Tuesday, April 30th, Thomas Bartrum sold 2,252 shares of Privia Health Group stock. The stock was sold at an average price of $18.42, for a total transaction of $41,481.84.

Privia Health Group Stock Up 0.3 %

PRVA stock opened at $18.05 on Wednesday. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 120.33, a PEG ratio of 2.39 and a beta of 0.81. The business has a fifty day simple moving average of $19.18 and a 200-day simple moving average of $20.89. Privia Health Group, Inc. has a 52 week low of $16.90 and a 52 week high of $29.42.

Privia Health Group (NASDAQ:PRVAGet Free Report) last posted its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $440.80 million for the quarter, compared to analyst estimates of $425.81 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. The firm’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period last year, the company posted $0.14 EPS. As a group, analysts expect that Privia Health Group, Inc. will post 0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Privia Health Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Covestor Ltd raised its position in Privia Health Group by 8.3% in the third quarter. Covestor Ltd now owns 6,703 shares of the company’s stock valued at $154,000 after purchasing an additional 514 shares during the period. Yousif Capital Management LLC raised its holdings in shares of Privia Health Group by 1.1% during the 4th quarter. Yousif Capital Management LLC now owns 52,628 shares of the company’s stock valued at $1,212,000 after buying an additional 563 shares during the period. New York State Common Retirement Fund lifted its position in Privia Health Group by 2.7% during the 3rd quarter. New York State Common Retirement Fund now owns 27,966 shares of the company’s stock worth $643,000 after acquiring an additional 737 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Privia Health Group by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,970 shares of the company’s stock worth $176,000 after acquiring an additional 756 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in Privia Health Group by 0.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 107,711 shares of the company’s stock worth $2,477,000 after acquiring an additional 976 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on PRVA shares. Bank of America cut shares of Privia Health Group from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $27.00 to $21.00 in a research note on Thursday, February 22nd. TD Cowen dropped their price target on Privia Health Group from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. Truist Financial reduced their price objective on Privia Health Group from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Evercore ISI dropped their price objective on Privia Health Group from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Finally, UBS Group cut their target price on shares of Privia Health Group from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, March 1st. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.67.

Read Our Latest Report on PRVA

About Privia Health Group

(Get Free Report)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

See Also

Insider Buying and Selling by Quarter for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.